MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejpb.2025.114810

Медицинская библиотека · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2025

Evaluating the efficacy of nintedanib-invasomes as a therapy for non-small cell lung cancer.

Mahmoud Tamer Mohamed, AbdElrahman Mohamed, Attia Mary Eskander, Nagib Marwa M, Fouad Amr Gamal, Belal Amany, Ali Mohamed A M, Aref Albezrah Nisreen Khalid, Al-Ziyadi Shatha Hallal, Abdelfattah Khalil Sherif Faysal, Shahataa Mary Girgis, Mahmoud Dina M

СтатьяПеревод в очереди

Аннотация

Nintedanib (NDB) is a crucial tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC). However, its oral administration results in limited uptake of NDB by the lungs, necessitating high and frequent dosages, which leads to severe systemic adverse effects and poor bioavailability. To address these issues, a nasal formulation of NDB-invasomes (NLI) was developed as a potential therapy for NSCLC, aiming to improve the sustainability, targeting, bioavailability, and efficacy of NDB. Utilizing design expert software, various formulations were created and optimized. Additionally, analyses were performed on the cytotoxicity, bioavailability, targeting, and toxicity of the optimized NLI formulation. The chosen formulation contained 1.723 % phospholipids, 1.5 % cineole, and 1 % ethanol. The optimized NLI formulation enhanced the sustainability and bioavailability of free NDB by 55 % and 7.93-fold, respectively. Targeting studies indicated that the NLI formulation could achieve a more localized accumulation of NDB in the lungs. Furthermore, the optimized NLI formulation demonstrated greater anticancer efficacy against A549 lung cancer cells than free NDB. Histopathological analysis of the lungs in the optimized NLI group revealed no signs of toxicity. These findings suggest that the nasal NLI formulation is a promising option for treatment of NSCLC.

Для цитирования: Mahmoud Tamer Mohamed, AbdElrahman Mohamed, Attia Mary Eskander, Nagib Marwa M, Fouad Amr Gamal, Belal Amany, Ali Mohamed A M, Aref Albezrah Nisreen Khalid, Al-Ziyadi Shatha Hallal, Abdelfattah Khalil Sherif Faysal, Shahataa Mary Girgis, Mahmoud Dina M. Evaluating the efficacy of nintedanib-invasomes as a therapy for non-small cell lung cancer.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2025. DOI: 10.1016/j.ejpb.2025.114810.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.